Genito-Urinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD.
Genito-Urinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD.
Mayo Clin Proc. 2015 Dec;90(12):1719-33. doi: 10.1016/j.mayocp.2015.10.010.
During the past several years, there has been substantial progress in the development of treatments for advanced prostate cancer with the approval of multiple new life-prolonging agents using different mechanisms of action. Such progress was attainable because of advances in our understanding of the biology behind mechanisms of androgen receptor pathway activation, complex tumor-microenvironment interaction of bone metastasis, antitumor immunology, and new oncogenic pathways. Continuous efforts are being made to develop new therapeutics with novel mechanisms of action, define the optimal sequences and/or combinations of current agents, and identify reliable surrogate end points to facilitate new drug development.
在过去的几年中，随着多种作用机制的新型延长生命药物的批准，晚期前列腺癌的治疗取得了实质性进展。之所以取得这样的进展，是因为我们对雄激素受体通路激活机制背后的生物学、骨转移的复杂肿瘤微环境相互作用、抗肿瘤免疫学和新致癌途径的理解有了进步。目前正在继续努力开发具有新型作用机制的新疗法，确定当前药物的最佳顺序和/或组合，并确定可靠的替代终点，以促进新药的开发。
